Epigenetic modulators have been previously shown to enhance the response of triple negative breast cancer (TNBC) cells to hormonal therapy through restoration or upregulation of the Estrogen Receptor-α (ERα) (19, 20). The gene discussed is ESR1; the disease is triple-negative breast carcinoma.